Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology

COHORT 1 Inclusion Criteria: * Histologically confirmed cutaneous or mucosal melanoma (per American joint committee on cancer (AJCC) staging system) that is unresectable or metastatic * No prior systemic anticancer therapy for unresectable/metastatic melanoma or clinical/radiological disease progression (RECIST1.1) if previously treated and before new treatment * No prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as cutaneous carcinoma or cervix) * followed in Saint Louis Hospital * Tumor tissue available in Saint Louis Hospital * Subjects must have signed and approved written informed consent form * No pregnancy * Any positive test for hepatitis A virus, hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus Exclusion Criteria: * None COHORT 2 : Inclusion Criteria : * Histologically confirmed cutaneous or mucosal melanoma * Candidates for sentinel lymph node analysis and surgical recovery (this examination is in practice reserved for melanomas \>1mm thick or ulcerated) * No prior adjuvant anticancer therapy * followed in Saint Louis Hospital * Tumor tissue available in Saint Louis Hospital * Subjects must have signed and approved written informed consent form * No pregnancy * Any positive test for hepatitis A virus, hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus Exclusion Criteria: * None